Cargando…

Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data

BACKGROUND: Papillary renal cell carcinoma type 2 (PRCC2) is refractory to systemic treatment and has a dismal prognosis. Previous studies showed that genetic alterations in PRCC2 were heterogeneous regardless of germline or somatic mutations. In this study, we aimed to perform precision treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ji-Yeon, Jeong, Hyoung-Oh, Heo, Dae Seog, Keam, Bhumsuk, Moon, Kyung Chul, Kwak, Cheol, Jang, Jinho, Kim, Seunghoon, Kim, Jong-Il, Lee, Semin, Lee, Se-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723617/ https://www.ncbi.nlm.nih.gov/pubmed/33313134 http://dx.doi.org/10.21037/atm-20-3466

Ejemplares similares

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
por: Choi, Younak, et al.
Publicado: (2015)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
por: Park, Sehhoon, et al.
Publicado: (2018)

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
por: Ha, Hyerim, et al.
Publicado: (2016)

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
por: Lee, June-Koo, et al.
Publicado: (2015)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
por: Cha, Soojin, et al.
Publicado: (2016)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Keam, Bhumsuk, et al.
Publicado: (2014)

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
por: Keam, Bhumsuk, et al.
Publicado: (2013)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
por: Lee, Jeongjae, et al.
Publicado: (2022)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
por: Sim, Sung Hoon, et al.
Publicado: (2015)

Use of high‐flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life
por: Kim, Jung Sun, et al.
Publicado: (2023)

Hospice-Palliative Medicine as a Model of Value-Based Healthcare
por: Heo, Dae Seog, et al.
Publicado: (2022)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
por: Yoo, Shin Hye, et al.
Publicado: (2021)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer
por: Koo, Tae Ryool, et al.
Publicado: (2012)

Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
por: Heo, Dae Seog, et al.
Publicado: (2022)

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
por: Park, Changhee, et al.
Publicado: (2021)

Microbiome of Saliva and Plaque in Children According to Age and Dental Caries Experience
por: Lee, Eungyung, et al.
Publicado: (2021)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives
por: Koh, Su-Jin, et al.
Publicado: (2018)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Jung, Eun Hee, et al.
Publicado: (2021)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

The Degree of Glycemic Control for the First Three Months Determines the Next Seven Years
por: Lee, Nami, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n8jmrmb5qhdrnck8keso4u20qn